Toward personalized and integrated treatment of patients with COPD;Hacia un tratamiento individualizado e integrado del paciente con EPOC

Archivos de Bronconeumologia

Volumn 46, Issue SUPPL.10, 2010, Pages 14-18

  Ancochea, Julio ^a   García, Teresa Gómez ^b   de Miguel Díez, Javier ^b  

^a Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Chronic obstructive pulmonary disease; Individualized treatment; Phenotypes

Indexed keywords

AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE COURSE; DISEASE SEVERITY; HUMAN; LUNG FUNCTION; PERSONALIZED MEDICINE; PHENOTYPE; SPIROMETRY; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; BRONCHODILATOR AGENTS; CASE MANAGEMENT; COMBINED MODALITY THERAPY; COMORBIDITY; EXPECTORANTS; GENE THERAPY; HUMANS; INDIVIDUALIZED MEDICINE; OXYGEN INHALATION THERAPY; PATIENT EDUCATION AS TOPIC; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING CESSATION;

EID: 79851492103     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S0300-2896(10)70051-X     Document Type: Article

References (34)

1. Peces-Barba G., Barberá J.A., Agustí A., Casanova C., Casas A., Izquierdo J.L. Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol 2008, 44:271-281.
2. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
3. Vestbo J., Anderson W., Coxson H.O., Crim C., Dawber F., Edwards L., et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008, 31:869-873.
4. Celli B.R., Cote C.G., Marin J.M., Casanova C., Montes de Oca M., Méndez R.A., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012.
5. Jones P.W., Harding G., Berry P., Wiklund I., Chen W.H., Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J 2009, 34:648-654.
6. Nishimura K., Izumu T., Tsukino M., Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002, 121:1434-1440.
7. Soler-Cataluña J.J., Martínez-García M.A., Román Sánchez P., Salcedo E., Navarro M., Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 60:925-931.
8. Anzueto A., Leimer I., Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J COPD 2009, 4:245-251.
9. Manzini G.J., Etminan M., Zhang B., Levesque L.E., FtizGerald M., Brophy J.M. Reduction of morbidity and mortiality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptors blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006, 47:2557-2560.
10. Estrategia en EPOC del Sistema Nacional de Salud. Madrid: Ministerio de Sanidad y Política Social; 2009.
11. Soler Cataluña J.J., Martínez-García M.A., Sánchez Sánchez L., Perpiñá Tordera M., Román Sánchez P. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med 2009, 103:692-699.
12. Puhan M.A., García-Aymerich J., Frey M., Ter Riet G., Antó J.M., Agust A.G., et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009, 374:704-711.
13. Dornhorst A.C. Respiratory insufficiency. Lancet 1955, 268:1183-1187.
14. De Lucas-Ramos P., López S., Lucero S., Juárez C., Rodríguez J.M. Fenotipos de la EPOC. Rev Patol Resp 2009, 12(Supl 2):176-182.
15. García-Aymerich J., Agustí A., Barberá J., Belda J., Farrero E., Ferrer A., et al. La heterogeneidad fenotípica de la EPOC. Arch Bronconeumol 2009, 45:129-138.
16. García-Aymerich J., Gómez F.P., Antó J.M. Caracterización fenotípica y evolución de la EPOC en el estudio PAC-COPD: diseño y metodología. Arch Bronconeumol 2009, 45:4-11.
17. O'Donnell D.E., Aaron S., Bourbeau J., Hernández P., Marciniuk D., Balter M., et al. Canadian Thorathic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007, 14(Suppl B):5B-32B.
18. Bourbeau J., Julien M., Maltais F. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003, 163:585-591.
19. Miravitlles M. Tratamiento individualizado de la EPOC: una propuesta de cambio. Arch Bronconeumol 2009, 45(Supl 5):27-34.
20. Rutten-van Mölken M., Oostenbrink J.B., Miratvilles M., Monk B.U. Modelling the 5 year cost-effectiveness of tiotropium, salmeterol and ipratropium for the treatment of COPD in Spain. Eur J Health Econ 2007, 8:123-135.
21. Rabe K.F., Timmer W., Sagkriotis A., Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008, 134:255-262.
22. Celli B.R., Thomas N.E., Anderson J.A., Ferguson G.T., Jerkins C.R., Jones P.W., et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study. Am J Respir Crit Care Med 2008, 178:332-338.
23. Jenkins C.R., Jones P.W., Calverley P.M., Celli B., Anderson J.A., Ferguson G.T., et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomized, placebo-controlled TORCH study. Respir Res 2009, 10:59.
24. Bleecker E.R., Emmett A., Crater G., Knobil K., Kalberg C. Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. Pulm Pharmacol Ther 2008, 21:682-688.
25. Miratvilles M. Nuevos tratamientos en la enfermedad pulmonar obstructiva crónica. Med Clin (Barc) 2005, 125:65-74.
26. Arnalich Jiménez B., Cano Pumarega I., Mola Ausiro A., Izquierdo Alonso J.L. Novedades en la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 2009, 45(Supl 3):9-13.
27. López-Campos J.L. Estrategias de tratamiento en la enfermedad pulmonar obstructiva crónica: una propuesta de sistematización. Arch Bronconeumol 2010, Epub ahead of print.
28. Alsaeedi A., Sin D.D., McAlister F.A. The effect of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002, 113:59-65.
29. Price D., Chisholm A., Ryan D., Crockett A., Jones R. The use of roflumilast in COPD: a primary care perspective. Prim Care Respir J 2010, Epub ahead of print.
30. Schonhofer B., Wenzel M., Geibel M., Kholer D. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit Care Med 1998, 26:1824-1828.
31. Schonhofer B., Bohrer H., Kohler D. Blood transfusion facilitating difficult weaning from ventilatior. Anaesthesia 1998, 53:181-184.
32. Pena X., Van Den Eynde E., Mena E., Recio J. EPOC y enfermedad cardiovascular. Rev Clin Esp 2007, 207(Supl 1):14-21.
33. Poole P.J., Black P.N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: a systematic review. BMJ 2001, 322:1271-1274.
34. Palmer L.J., Celedon J.C., Chapman H.A., Speizer F.E., Weiss S.T., Silverman E.K. Genome-wide linkage analysis of bronchodilatos responsiveness and post-bronchodilator spirometric phenotypes in chronic obstructive pulmonary disease. Hum Molec Genet 2003, 12:1199-1210.